IgA Nephropathy (IgAN) Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

August 01 09:04 2020
IgA Nephropathy (IgAN) Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

“IgA Nephropathy (IgAN) – Market Insights, Epidemiology, and Market Forecast-2030”


DelveInsight has launched a new report on “IgA Nephropathy (IgAN) – Market Insights, Epidemiology, and Market Forecast-2030”.


DelveInsight’s “IgA Nephropathy (IgAN) – Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the IgA Nephropathy (IgAN) , historical and forecasted epidemiology as well as the IgA Nephropathy (IgAN) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


Some of the key facts:

  1. IgA Nephropathy is more common in men than women.
  2. The prevalence is modest in the United States (10–20% of primary glomerulonephritis), higher in some European countries (20–30%) and highest in developed countries in Asia (40–50%).
  3. A systematic review of biopsy-based studies spanning multiple countries suggests an overall population incidence of at least 2.5 per 100,000. Only one study in this review was from Japan, and most were from Europe and North America.
  4. According to the surveyed literature, this disorder is thought to follow a benign course in most cases. However, many patients are at risk for slow progression to ESRD, which develops in approximately 15% of patients by 10 years and 20% by 20 years, though these percentages depend on how the disease is defined.


Scope of the Report:

  • The report covers the descriptive overview of IgA Nephropathy (IgAN) , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the IgA Nephropathy (IgAN) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for IgA Nephropathy (IgAN) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of IgA Nephropathy (IgAN) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global IgA Nephropathy (IgAN) market


Request for Free Sample Page: https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market


IgA nephropathy, also known as Berger’s disease, is a kidney disease that occurs when IgA deposits build up in the kidneys, causing inflammation that damages kidney tissues. IgA is an antibody—a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses. Most people with IgA nephropathy receive care from a nephrologist, a doctor who specializes in treating people with kidney disease.


People who have this condition most often present with one or recurrent episodes of having blood in their urine (visible hematuria). These episodes usually occur during or right after an upper respiratory tract infection such as a cold, sore throat or a gastrointestinal infection.

IgA nephropathy usually doesn’t cause symptoms in the early stages, so the disease can go unnoticed for years or decades. It’s sometimes suspected when routine tests reveal protein and red blood cells in your urine that can’t be seen without a microscope (microscopic hematuria). In its early stages, IgA nephropathy may have no symptoms; it can be silent for years or even decades. Once symptoms appear, the most common one is hematuria, or blood in the urine. Hematuria can be a sign of damaged glomeruli. Blood in the urine may appear during or soon after a cold, sore throat, or other respiratory infection. The amount of blood may be: visible with the naked eye. The urine may turn pink or the color of tea or cola. Sometimes a person may have dark or bloody urine so small that it can only be detected using special medical tests.

Another symptom of IgA nephropathy is albuminuria—when a person’s urine contains an increased amount of albumin, a protein typically found in the blood, or large amounts of protein in the urine.


Request for Free Sample Page: https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market


Key Companies Covered:

  • Novartis
  • Omeros Corporation
  • Calliditas Therapeutics
  • Apellis Pharmaceuticals
  • Aravive
  • Ionis
  • Aduro
  • And Many Others


Some of the Drugs Covered:

  • AVB-S6-500
  • BION-1301
  • And Many Others.


Request for Free Sample Page: https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market


Table of Contents:

1. Key Insights

2. Executive Summary of IgA Nephropathy (IgAN)

3. Competitive Intelligence Analysis for IgA Nephropathy (IgAN)

4. IgA Nephropathy (IgAN) : Market Overview at a Glance

5. IgA Nephropathy (IgAN) : Disease Background and Overview

6. Patient Journey

7. IgA Nephropathy (IgAN) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of IgA Nephropathy (IgAN) Treatment

11. Marketed Products

12. Emerging Therapies

13. IgA Nephropathy (IgAN) : Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of IgA Nephropathy (IgAN)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight


Request for Detailed TOC: https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/iga-nephropathy-igan-market